Research programme: birch pollen allergy immunotherapy - Immunotek
Alternative Names: Bet-v1 viscogel; Birch pollen viscogel; Viscogel-Bet v 1Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Lytix Biopharma
- Developer Immunotek SL; Lytix Biopharma; Viscogel AB
- Class Allergens; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Seasonal allergic rhinitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Seasonal-allergic-rhinitis in European Union (Sublingual, Gel)
- 10 Sep 2013 Early research in Seasonal allergic rhinitis in European Union (Sublingual)